NEJM (@nejm) 's Twitter Profile
NEJM

@nejm

The New England Journal of Medicine is the world’s leading medical journal and website.

ID: 25950355

linkhttp://NEJM.org calendar_today23-03-2009 04:10:07

34,34K Tweet

934,934K Followers

430 Following

NEJM (@nejm) 's Twitter Profile Photo
NEJM
@nejm

a year ago

KEYNOTE-564 trial: Improved survival in renal-cell cancer after 1 year of adjuvant therapy was seen with pembrolizumab. At 4 years, 91% of pembrolizumab-treated patients were alive, as compared with 86% of those who received placebo after surgery. nej.md/3TVLuKz

KEYNOTE-564 trial: Improved survival in renal-cell cancer after 1 year of adjuvant therapy was seen with pembrolizumab. At 4 years, 91% of pembrolizumab-treated patients were alive, as compared with 86% of those who received placebo after surgery. nej.md/3TVLuKz